<DOC>
	<DOC>NCT02210208</DOC>
	<brief_summary>An open, non controlled, multi-centre, clinical investigation to verify performance and safety of a soft silicone wound contact layer containing silver in the treatment of skin grafts in surgical burn patients and the usefulness of a marketed donor site dressing.</brief_summary>
	<brief_title>An Open, Non Controlled, Multi-centre, Clinical Investigation to Verify Performance and Safety of a Soft Silicone Wound Contact Layer Containing Silver in the Treatment of Skin Grafts in Surgical Burn Patients and the Usefulness of a Marketed Donor Site Dressing.</brief_title>
	<detailed_description />
	<mesh_term>Burns</mesh_term>
	<criteria>Part A Inclusion Criteria Subjects with burn injury resulting in up to 30% TBSA Full thickness area of burn should not be more than 20% Area in need of skin grafting can be 115% TBSA Study site area must have healthy, intact periwound skin surrounding it to allow for adequate overlap of study product Thermal injuries only Subjects age 18 months to &lt; 65 years. Signed informed consent Subjects who are younger than the legal consenting age must in addition to their own assent form have a signature from a legally authorized representative. Exclusion Criteria Greater than 30% TBSA Full thickness areas greater than 20% TBSA Full thickness area to be grafted less than 1% Presence of respiratory involvement Subjects on mechanical ventilation Subjects with infected burn wounds Subjects with organ failure Diagnosed underlying disease(s) (e.g. HIV/AIDS, cancer and severe aeaemia) judged by the investigator to be a potential interference in the treatment Subjects treated with systemic glucocorticosteroids, except patients taking occasional doses or doses less than 10mg prednisolone/day or equivalent Known allergy/hypersensitivity to any of the components of the investigation products. Subjects with physical and/or mental conditions that are not expected to comply with the investigation, including patients totally confined to bed Participation in other clinical investigation(s) within 1 month prior to start of the investigation Previous randomized to this investigation Part B Inclusion Criteria There must be healthy, intact periwound skin surrounding the planned donor site to allow for adequate overlap of study product (5 cm) Exclusion Criteria Investigator do not agree to treat the donor site with Mepilex Transfer Ag The subject do not agree to participate in the donor site part</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>